NCT00000962View on ClinicalTrials.gov

The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Nevirapine

Trial Locations (3)

55455

Univ of Minnesota, Minneapolis

921036325

Univ of California / San Diego Treatment Ctr, San Diego

01655

Univ of Massachusetts Med Ctr, Worcester

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000962 - The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients | Biotech Hunter | Biotech Hunter